Vice Chancellor Paul Fioravanti has determined the head of a pain management drug developer breached contracts with a Sorrento Therapeutics-backed company by diverting opportunities and trade secrets to a newly formed competitor.

The Sept. 1 post-trial decision to hold Anthony Mack and Virpax, the West Chester, Pennsylvania-based company for which Mack is the chairman and CEO, liable is a win for the Latham & Watkins and Morris, Nichols, Arsht & Tunnell team that represented Sorrento and Scilex Pharmaceuticals, though Fioravanti has asked for additional briefing to determine what remedy he’ll grant.